Stock IdeasStrong Buy Stocks

Strong Buy Stocks from Top Wall Street Analysts

Latest stocks with a Strong Buy rating from the top performing 25% of analysts tracked by WallStreetZen

Canaccord Genuity's Whitney Ijem raised their price target on Pharming Group NV (NASDAQ: PHAR) by 2.7% from $37 to $38 on 2026/08/04. The analyst maintained their Strong Buy rating on the stock.

Pharming Group NV reported its Q2 2026 earnings.

Raising their price target, Ijem decribed the quarter's results as "mixed," citing a Ruconest miss and a slight Joenja beat.

Earnings Report

For Q2 2026, Pharming Group NV reported:

• EPS of $0.002, down from Q2 2025's 0.006.
• Revenue of $90.2M, down 3% Y/Y.

Management did not provide financial guidance in its press release.

CEO Fabrice Chouraqui commented: “While we have lowered our full-year revenue guidance, we are encouraged by the resilience of RUCONEST, a year after the launch of the first oral on-demand HAE treatment.

"The active patient base remained at 93% of year ago levels, and RUCONEST continues to be a cornerstone on-demand treatment for high burden HAE patients.

"Supported by strong new patient enrollments in the second quarter, we expect RUCONEST revenues to stabilize and return to growth during the second half of 2026.

"Joenja (leniolisib) continued to build momentum in APDS, supported by expansion into additional geographies.

"Beyond APDS, we are encouraged by the potential for leniolisib in broader populations with primary immunodeficiencies, including CVID, where the PI3Kδ pathway is seen as a key driver of immune dysregulation, and we look forward to reporting data from two clinical trials in the fourth quarter of 2026.

"As we continue to implement a more disciplined operating model, reflected in our improved full-year operating expense guidance, Pharming is evolving into a more diversified rare disease company with a high-value pipeline that has the potential to materially increase our scale and strengthen our long-term growth profile.”